This review highlights the significant morbidity, mortality, and healthcare costs associated with DVT and PE, emphasizing the importance of prevention, early diagnosis, and treatment.
VTE imposes major annual US burden with high recurrence; leaves open optimal prevention strategies in acute settings.
Deep vein thrombosis and its complications, including pulmonary embolism, are major health problems in the United States, resulting in more than 260,000 hospital admissions and 100,000 deaths each year. Thirty percent of patients diagnosed with deep vein thrombosis will experience at least one recurrence of symptoms. To minimize patient morbidity and mortality and to contain health care costs, prevention, early diagnosis, and treatment of these conditions are essential. In this article the incidence pathophysiology risk factors, and clinical course of deep vein thrombosis and pulmonary embolism are discussed, as well as the clinician's role in prevention and treatment.
No takes yet. Share an insight, caveat, or question.
Launius et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: